Piper Sandler upgraded Solid Biosciences to Overweight from Neutral with a $20 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SLDB:
- Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
- Solid Biosciences price target raised to $16 from $9 at H.C. Wainwright
- SLDB Upcoming Earnings Report: What to Expect?
- Solid Biosciences announces licensing agreement with Armatus Bio
- Solid Biosciences files to sell 19.685M shares of common stock for holders